<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cancer Immunotherapy on FinanClub</title>
    <link>https://finan.club/tags/cancer-immunotherapy/</link>
    <description>Recent content in Cancer Immunotherapy on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 13 Mar 2024 09:07:26 +0000</lastBuildDate><atom:link href="https://finan.club/tags/cancer-immunotherapy/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IOVA</title>
      <link>https://finan.club/us/iova/</link>
      <pubDate>Wed, 13 Mar 2024 09:07:26 +0000</pubDate>
      
      <guid>https://finan.club/us/iova/</guid>
      <description>score:-12
Chances: Iovance Biotherapeutics&amp;rsquo; revenue is set to grow, indicating potential for increased stock value. The FDA has lifted a partial clinical hold on Iovance&amp;rsquo;s mid-stage study, showing positive regulatory progress. Risks: Iovance Biotherapeutics reported a net loss of $116.4 million in Q4, reflecting financial risk and potential impact on stock performance.</description>
    </item>
    
  </channel>
</rss>
